Trendbrott när kostnaden för inhyrd vårdpersonal minskar

Regionernas beroende av hyrbemanning minskar för första gången på flera år.

ZEISS Microscope has been Optimized for Capturing Subcellular Structures and their Dynamics

Live imaging with uniform super-resolution in all spatial dimensions.

Achieve Efficient, Fast Targeting of Your Sample

Step into the future of imaging technology with VersaXRM 730.

The stomach medication that became the biggest blockbuster of the 1990s

The omeprazole molecule was synthesised as early as 1979, but it took many years before the then Astra had an approved pharmaceutical. Once this happened, a tab...

Anna Törner: Success requires bold decisions!

“Doing things right is fine, but doing the right things as soon as possible is even better”, writes Anna Törner in a column.

Investments worth 40 billion in the Öresund region – “A huge investment wave”

A new report reveals that medical companies in the Oresund region are investing like never before.

Event: Drug Development – Serendipity or Science

Drug development is a challenging journey, we will discuss questions you may not even consider asking. SDS and Medicon Village welcome you to an engaging afternoon.

Why the world renown researcher Marc Tessier-Lavigne resigns as Stanford´s president

In mid-summer, neuroscientist Marc Tessier-Lavigne announced his resignation as President of Stanford following allegations of manipulated study data. According...

Tio life science-projekt får miljonanslag – ny utlysning öppnar

En rad life science-projekt har fått miljonanslag i ett svenskt proof of concept-program. 13 januari öppnar en ny utlysning.

Inget statligt stöd för fetmaläkemedel – aktien för läkemedelsjättar pressas

Trump-administrationen slopar Bidens förslag om att om att inkludera fetmaläkemedel i sjukförsäkringen Medicare. Det innebär ett bakslag för Novo Nordisk och El...

Novavax is developing a vaccine candidate against Covid-19 and seasonal flu

A combined vaccine against both Covid-19 and seasonal flu is showing promising results in studies, according to the American drug developer Novavax. The adjuvan...

Are you ready for EMC 2024?

Visit ZEISS at Europe’s largest Event dedicated to Microscopy and Imaging.

Optimize Your Visibility

ZEISS presents our newest VersaXRM® 730 3D X-ray microscope.

Column: Repurposing as a golden ticket to approval

"Hopefully, in the end, patients will be winners by receiving on-label treatments for which benefit-risk has been properly assessed." In a column Marie Gårdmark...

Italian pharmaceutical company buys rights to immunotherapy from Sanofi

Italy's Recordati buys the rights to a treatment for the rare autoimmune disease cold agglutinin disease (CAD).

Thumbs down for lecanemab in the EU – “Very surprised”

The Azheimer's drug lecanemab has received a negative assessment from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP), acc...

Gothenburg, the city of life science – We are ‘Little Boston’

Western Sweden is investing in life science within everything from advanced therapeutic drugs to femtech. At the same time, stakeholders are looking to other in...

Healthcare study: Alzheimer’s blood test shows high accuracy

A blood test for identifying Alzheimer’s has now been tested in the general healthcare setting. According to the researchers, the test was 90% accurate in making a diagnosis.

A small thing that can solve your problems

If you are in need of a compact valve. Look no further! We have the VOVK

Claims of life science companies fleeing abroad is a myth according to survey

The claim that life science companies are moving abroad is exaggerated. In fact, only a tiny percentage is leaving the country, according to a survey.

Snabbtest ska säkra rätt hormonbehandling inför IVF

Forskare i Lund har tagit fram ett test som på en timme kan ge besked om vilken hormonbehandling som är mest lämplig inför en provrörsbefruktning, och som därme...

TFS Trial Form Support AB

Bioscience – Groundbreaking Research & Diagnostics: Stockholm (2026)

MSD discontinues two Keytruda trials

MSD has stopped two late-stage trials that tested its blockbuster immunotherapy Keytruda as a treatment for skin and lung cancer.